In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

Hau, Desmond Kwok Po; Zhu, Guo‐Yuan; Leung, Alexander Kai-man; Wong, Raymond Siu Ming; Cheng, Gregory Yin Ming; Lai, Paul B.S.; Tong, Sze Wai; Lau, Fung Yi; Chan, Kwong Wah; Wong, Wai Yeung; Lam, Kim Hung; Cheng, Chor Hing; Cheung, Filly; Chui, Chung Hin; Gambari, Roberto; Fong, David

doi:10.1016/j.phymed.2010.09.001

Cited by 46 publications

(39 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research has focused on herbal medicines, among which, corilagin is a novel anticancer agent. This drug was confirmed to inhibit cancer growth involving multiple pathways (8)(9)(10)(11). Corilagin was reported to have the following characteristics: non-toxicity to normal tissues, a wide spectrum of efficacy against multiple cancers, and ability for oral consumption.…”

Section: Discussionmentioning

confidence: 92%

“…In the past few decades, corilagin has been reported to display several pharmacological activities, including antioxidant (2), hepatoprotective (3), anti-inflammatory (4), neural system protective (5) and cardiovascular protective (6) activities, and has been found to be beneficial in managing type 2 diabetes (7). Recently, its antitumor effects in hepatocellular carcinoma (8,9), ovarian cancer (10) and cholangiocarcinoma (11) have attracted attention.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail-glycolysis pathways

et al. 2017

View full text Add to dashboard Cite

Abstract. We identified that corilagin is a major component extracted from a well-known hepatoprotective and antiviral medicinal herb, Phyllanthus niruri L with antitumor activity. Our previous study found that corilagin inhibited the growth of ovarian cancer cells via the TGF-β/AKT/ERK signaling pathways. Recently, we demonstrated that corilagin enhanced the sensitivity of ovarian cancer cells to chemotherapy. Ovarian cancer cell lines, SKOv3ip, Hey and HO-8910PM-Snail, were treated with different concentrations of corilagin in combination with paclitaxel and carboplatin. Corilagin distinctly enhanced the inhibitory effects of paclitaxel and carboplatin. To understand the mechanisms involved in the chemo-sensitization by corilagin, we performed reverse phase protein array analysis to determine the signaling networks induced by corilagin. We observed that both paclitaxel and carboplatin upregulated the expression levels of several apoptotic and death-related proteins, such as caspase 3, caspase 7 and PDCD4, which were further enhanced when combined with corilagin. Meanwhile, corilagin induced distinct pathways to paclitaxel and carboplatin treatment. We also performed isobaric tags for relative and absolute quantitation proteomics analysis in corilagen-treated ovarian cancer cells. This analysis indicated that corilagin is mainly involved in the glycolysis pathway. Seahorse XF96 extracellular acidification rate analysis confirmed that corilagin inhibited glycolysis by downregulation of CD44 and STAT3. In summary, our observations indicate that corilagin sensitized epithelial ovarian cancer cells to paclitaxel and carboplatin treatment by primarily inhibiting Snail-glycolysis pathways. Corilagin is a herbal medicine with low toxic effects to normal cells, particularly hepatoprotective, and may be an ideal complimentary medicine when combined with highly toxic chemotherapeutic agents. IntroductionCorilagin (C 27 H 22 O 18 ), a gallotannin found in many plants, is a major active component of many ethnopharmacological plants, such as Phyllanthus niruri L., P. emblica L. and P. urinaria L. Corilagin was first isolated in 1951 by Schmidt and Lademann from Divi-divi (Caesalpina coriaria) plants (1). In the past few decades, corilagin has been reported to display several pharmacological activities, including antioxidant (2), hepatoprotective (3), anti-inflammatory (4), neural system protective (5) and cardiovascular protective (6) activities, and has been found to be beneficial in managing type 2 diabetes (7). Recently, its antitumor effects in hepatocellular carcinoma (8,9), ovarian cancer (10) and cholangiocarcinoma (11) have attracted attention.Since 2005, we screened hundreds of herbs, among which Phyllanthus niruri L. has the highest anticancer potential. The present study further identified that corilagin is a major active component from P. niruri L. extracts and has broadspectrum antitumor activity, a better antitumor potential but lower toxicity to normal cells (12). It is effective in retarding the growth of he...

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail-glycolysis pathways

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Starting from crude methanolic extracts of the aerial parts of P. urinaria and employing a sequence of three conventional steps including liquid-liquid distribution, gel permeation over Sephadex LH-20 and repeated reversed-phase HPLC chromatography, a very high yield of corilagin was obtained [22,23]. Corilagin (beta-1-O-galloyl-3,6-(R)-hexahydroxydiphenoyl-D-glucose) (Fig.…”

Section: Introductionmentioning

confidence: 99%

Corilagin is a potent inhibitor of NF-kappaB activity and downregulates TNF-alpha induced expression of IL-8 gene in cystic fibrosis IB3-1 cells

Gambari

Borgatti

Lampronti

et al. 2012

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

“…In comparison, human IPF is a chronic pathological process where epithelial injury, inflammation, mal-regeneration and fibrosis co-exist. These discrepancies well account for the fact that the anti-fibrotic efficacy of these agents obtained in IPF patients does not parallel that in animal models [3,22]. Therefore, further studies on corilagin are needed to fill the gap between the bench in alleviating experimental pulmonary fibrosis and the bedside in treating IPF.…”

Section: Resultsmentioning

confidence: 99%

“…The molecular formula of corilagin is C 27 H 22 O 18 , and its molecular weight is 634.45 (Figure 1). Corilagin has shown an extensive pharmacological spectrum, including antihypertensive, antiatherogenic, antitumor and thrombolytic effects, and has potential synergic effect with beta-lactams against methicillin-resistant Staphylococcus aureus [19,21,22]. Corilagin inhibits NF-κB signaling and the production of proinflammatory cytokines (e.g., IL-1β and TNF-α), and is able to eliminate oxidative radicals [23,24,25,26].…”

Section: Introductionmentioning

confidence: 99%

Corilagin Attenuates Aerosol Bleomycin-Induced Experimental Lung Injury

Zheng

Guo

Xiao-ju

et al. 2014

IJMS

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a progressing lethal disease with few clinically effective therapies. Corilagin is a tannin derivative which shows anti-inflammatory and antifibrotics properties and is potentiated in treating IPF. Here, we investigated the effect of corilagin on lung injury following bleomycin exposure in an animal model of pulmonary fibrosis. Corilagin abrogated bleomycin-induced lung fibrosis as assessed by H&E; Masson’s trichrome staining and lung hydroxyproline content in lung tissue. Corilagin reduced the number of apoptotic lung cells and prevented lung epithelial cells from membrane breakdown, effluence of lamellar bodies and thickening of the respiratory membrane. Bleomycin exposure induced expression of MDA, IKKα, phosphorylated IKKα (p-IKKα), NF-κB P65, TNF-α and IL-1β, and reduced I-κB expression in mice lung tissue or in BALF. These changes were reversed by high-dose corilagin (100 mg/kg i.p) more dramatically than by low dose (10 mg/kg i.p). Last, corilagin inhibits TGF-β1 production and α-SMA expression in lung tissue samples. Taken together, these findings confirmed that corilagin attenuates bleomycin-induced epithelial injury and fibrosis via inactivation of oxidative stress, proinflammatory cytokine release and NF-κB and TGF-β1 signaling. Corilagin may serve as a promising therapeutic agent for pulmonary fibrosis.

show abstract

In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

Cited by 46 publications

References 6 publications

Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail-glycolysis pathways

Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail-glycolysis pathways

Corilagin is a potent inhibitor of NF-kappaB activity and downregulates TNF-alpha induced expression of IL-8 gene in cystic fibrosis IB3-1 cells

Corilagin Attenuates Aerosol Bleomycin-Induced Experimental Lung Injury

Contact Info

Product

Resources

About